From the Affective Disorders Program, Department of Psychology, University of Bologna, Bologna, Italy; and the Department of Psychiatry, State University of New York at Buffalo, Buffalo, N.Y.
Am J Psychiatry. 2016 Feb 1;173(2):128-37. doi: 10.1176/appi.ajp.2015.15040476. Epub 2015 Oct 20.
A number of randomized controlled trials in major depressive disorder have employed a sequential model, which consists of the use of pharmacotherapy in the acute phase and of psychotherapy in its residual phase. The aim of this review was to provide an updated meta-analysis of the efficacy of this approach in reducing the risk of relapse in major depressive disorder and to place these findings in the larger context of treatment selection.
Keyword searches were conducted in MEDLINE, EMBASE, PsycINFO, and Cochrane Library from inception of each database through October 2014. Randomized controlled trials examining the efficacy of the administration of psychotherapy after successful response to acute-phase pharmacotherapy in the treatment of adults with major depressive disorder were considered for inclusion in the meta-analysis.
Thirteen high-quality studies with 728 patients in a sequential treatment arm and 682 in a control treatment arm were included. All studies involved cognitive-behavioral therapy (CBT). The pooled risk ratio for relapse/recurrence was 0.781 (95% confidence interval [CI]=0.671-0.909; number needed to treat=8), according to the random-effects model, suggesting a relative advantage in preventing relapse/recurrence compared with control conditions. A significant effect of CBT during continuation of antidepressant drugs compared with antidepressants alone or treatment as usual (risk ratio: 0.811; 95% CI=0.685-0.961; number needed to treat=10) was found. Patients randomly assigned to CBT who had antidepressants tapered and discontinued were significantly less likely to experience relapse/recurrence compared with those assigned to either clinical management or continuation of antidepressant medication (risk ratio: 0.674; 95% CI=0.482-0.943; number needed to treat=5).
The sequential integration of CBT and pharmacotherapy is a viable strategy for preventing relapse in major depressive disorder. The current indications for the application of psychotherapy in major depressive disorder are discussed, with special reference to its integration with pharmacotherapy.
一些重度抑郁症的随机对照试验采用了序贯模型,该模型包括急性期的药物治疗和残留期的心理治疗。本综述的目的是提供该方法在降低重度抑郁症复发风险方面的有效性的最新荟萃分析,并将这些发现置于治疗选择的更大背景下。
对 MEDLINE、EMBASE、PsycINFO 和 Cochrane Library 进行了关键词搜索,每个数据库的搜索均从建立开始至 2014 年 10 月。纳入了对急性药物治疗成功后给予心理治疗对成人重度抑郁症治疗效果的随机对照试验。
纳入了 13 项高质量的研究,序贯治疗组有 728 例患者,对照组有 682 例患者。所有研究均涉及认知行为疗法(CBT)。根据随机效应模型,复发/再发的合并风险比为 0.781(95%置信区间[CI]=0.671-0.909;需要治疗的人数=8),表明与对照条件相比,预防复发/再发有相对优势。与单独使用抗抑郁药或常规治疗相比,继续使用抗抑郁药物时 CBT 的效果显著(风险比:0.811;95%CI=0.685-0.961;需要治疗的人数=10)。与分配至临床管理或继续使用抗抑郁药物的患者相比,被随机分配至 CBT 并逐渐减少抗抑郁药物剂量和停药的患者发生复发/再发的可能性显著降低(风险比:0.674;95%CI=0.482-0.943;需要治疗的人数=5)。
CBT 和药物治疗的序贯整合是预防重度抑郁症复发的一种可行策略。本文讨论了目前在重度抑郁症中应用心理治疗的指征,特别强调了其与药物治疗的整合。